Type 1 Diabetes Care in Mexico: An Analysis of the RENACED-DT1 National Registry.

Autor:	Faradji-Hazán RN; Clínica EnDi, Mexico City; School of Medicine, Instituto Tecnológico de Monterrey, Mexico City, Mexico., Valenzuela-Lara M; Centro Nacional para la Prevención y el Control del VIH y el Sida, Mexico City, Mexico., Díaz-Barriga Menchaca AP; School of Medicine, Instituto Tecnológico de Monterrey, Mexico Cit, Mexico., Almeda-Valdes P; Department of Endocrinology and Metabolism, Metabolic Diseases Research Unit, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMyNSZ), Mexico City, Mexico., Antonio-Villa NE; Department of Endocrinology and Metabolism, Metabolic Diseases Research Unit, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMyNSZ), Mexico City; MD/PhD Programa de Estudios Combinados en Medicina (PECEM) Program, Faculty of Medicine, Universidad Nacional Autónoma de México (UNAM), Mexico City; Mexico., Vidrio-Velázquez M; Department of Endocrinology, Hospital General Regional # 110, Instituto Mexicano del Seguro Social (IMSS), Guadalajara, Jal., Mexico., Islas-Ortega L; Pediatric Endocrinology Service, Hospital del Niño DIF Hidalgo, Pachuca, Hgo., Mexico., Martínez-Ramos-Méndez A; Pediatric Endocrinology Service, Hospital Español, Mexico City, Mexico., de la Garza-Hernández NE; Private Practice in Endocrinology, Centro Médico Integral (CEMEDIN), Mty., NL, Mexico., Bustamante-Martínez JF; Department of Internal Medicine, Servicios de Salud de Nayarit- Hospital General de Tepic, Nay., Mexico., Sánchez-Ruiz KL; Clínica de Diabetes, Secretaría de Salud del Estado de Durango, Dgo., Mexico., Yepez-Rodríguez AE; Internal Medicine and Endocrinology Service, Corporativo Hospital Satélite, Mex., Mexico., González-Gálvez G; Instituto Jalisciense de Investigación en Diabetes y Obesidad, Guadalajara, Jal., Mexico., Niño-Vargas RS; Centro para la Prevención y Atención Integral del VIH/SIDA de la Ciudad de México, Mexico City, Mexico., Sainz de la Maza-Viadero ME; Clínica EnDi, Mexico City, Mexico., Magis-Rodríguez C; Faculty of Medicine, UNAM, Mexico City, Mexico.
Jazyk:	angličtina
Zdroj:	Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion [Rev Invest Clin] 2021 May 04; Vol. 73 (4), pp. 222-230. Date of Electronic Publication: 2021 May 04.
DOI:	10.24875/RIC.20000498
Abstrakt:	Background: Information regarding diagnosis, treatment, and follow-up of patients with type 1 diabetes (PWT1D) in Mexico is limited. We developed an on-line platform Registro Nacional de Pacientes con Diabetes Tipo 1 (RENACED-DT1). Objective: The objective of the study was to describe the characteristics and healthcare of PWT1D registered in RENACED-DT1. Methods: Analyses of 965 PWT1D from July 2014 to January 2018 in different endocrinology clinics around Mexico. Results: Sixty-one percent were female with median age of 21 years, age at diagnosis 11 years, and disease duration at inclusion 8.2 years. Treatment regimen was basal-bolus in 61% and insulin-pumps in 21% (mainly in the private sector); 33.3% with self-monitoring of blood-glucose (SMBG) ≥4 times/day. Mean HbA1c at last follow-up was 8.7 ± 2.1% (72±23 mmol/mol), 18% had HbA1c < 7% (53 mmol/mol), and 35% > 9% (75 mmol/mol). SMBG ≥ 4 times/day was associated with HbA1c < 7%. Time since diagnosis > 10 years, female sex, BMI ≥ 30 kg/m2, SMBG < 4 times/day, and any hypoglycemia were associated with microvascular complications (p < 0.05). Conclusions: Percentage of patients achieving HbA1c < 7% is low; increased blood glucose monitoring is associated with better glycemic control. The achievement of optimal glycemic control must be increased to reduce the incidence of chronic complications and improve quality of life in PWT1D.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu